Drugs Made In America Acquisition (DMAA) Invested Capital (2024 - 2026)

Drugs Made In America Acquisition (DMAA) has reported Invested Capital for 3 consecutive years, with -$7.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Invested Capital rose 1.34% year-over-year to -$7.1 million; the trailing twelve-month figure through Jun 2026 stood at -$7.1 million (up 1.34% YoY), and the FY2025 full-year result was -$7.3 million, down 772.71% from the prior year.
• Invested Capital improved to -$7.1 million in Q2 2026 per DMAA's latest filing, from -$7.3 million in the prior quarter.
• Across five years, Invested Capital topped out at $1.1 million in Q4 2024 and bottomed at -$7.3 million in Q3 2025.
• Historically, Invested Capital has averaged -$5.8 million across 3 years, with a median of -$7.1 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Invested Capital sank 772.71% in 2025, then climbed 1.34% in 2026.
• Over 3 years, Invested Capital stood at $1.1 million in 2024, then tumbled by 772.71% to -$7.3 million in 2025, then grew by 2.86% to -$7.1 million in 2026.
• According to Business Quant data, Invested Capital over the past three periods registered -$7.1 million, -$7.3 million, and -$7.3 million for Q2 2026, Q4 2025, and Q3 2025 respectively.